Sun Pharmaceutical Fundamentals 2025 — US Generic India Domestic Analysis
India's largest pharma company. Sun Pharma's specialty US business, domestic branded generics leadership, EBITDA margin trajectory, and SniperIQ AI signal analysis.
Frequently Asked Questions
What makes Sun Pharma different from other Indian pharma companies?
Sun Pharma has the highest specialty revenue mix among Indian generics — ~25% from complex/specialty drugs (Ilumya, Absorica, Winlevi) vs competitors who are mostly commodity generics. Specialty drugs carry 3-5x the margins of generics and face less pricing erosion.
Is Sun Pharma a good buy in 2025?
Sun Pharma offers a premium EBITDA margin story (27-30%), strong domestic branded generics, and a growing specialty US business. At 30-35x PE, it's not cheap, but quality commands premium. SniperIQ's AI signal helps time entries around FDA approval catalysts.
Track Sun Pharma on SniperIQ
SniperIQ monitors Sun Pharma's FDA approval pipeline, quarterly revenue by geography, specialty drug launches, and AI directional signal for SUNPHARMA.